KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to $55.7 million.

  • Halozyme Therapeutics' Other Non-Current Assets fell 3050.87% to $55.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.7 million, marking a year-over-year decrease of 3050.87%. This contributed to the annual value of $80.6 million for FY2024, which is 35237.99% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Other Non-Current Assets is $55.7 million, which was down 3050.87% from $56.4 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Other Non-Current Assets ranged from a high of $80.6 million in Q4 2024 and a low of $13.4 million during Q4 2021
  • Moreover, its 5-year median value for Other Non-Current Assets was $25.2 million (2023), whereas its average is $33.5 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first plummeted by 3226.11% in 2023, then skyrocketed by 35237.99% in 2024.
  • Halozyme Therapeutics' Other Non-Current Assets (Quarter) stood at $13.4 million in 2021, then skyrocketed by 96.07% to $26.3 million in 2022, then crashed by 32.26% to $17.8 million in 2023, then surged by 352.38% to $80.6 million in 2024, then tumbled by 30.89% to $55.7 million in 2025.
  • Its Other Non-Current Assets was $55.7 million in Q3 2025, compared to $56.4 million in Q2 2025 and $55.6 million in Q1 2025.